BACKGROUND: Total knee arthroplasty (TKA) relieves pain and improves quality of life for persons with advanced knee osteoarthritis. However, to our knowledge, the cost-effectiveness of TKA and the influences of hospital volume and patient risk on TKA cost-effectiveness have not been investigated in the United States. METHODS: We developed a Markov, state-transition, computer simulation model and populated it with Medicare claims data and cost and outcomes data from national and multinational sources. We projected lifetime costs and quality-adjusted life expectancy (QALE) for different risk populations and varied TKA intervention and hospital volume. Cost-effectiveness of TKA was estimated across all patient risk and hospital volume permutations. Finally, we conducted sensitivity analyses to determine various parameters' influences on cost-effectiveness. RESULTS: Overall, TKA increased QALE from 6.822 to 7.957 quality-adjusted life years (QALYs). Lifetime costs rose from $37,100 (no TKA) to $57 900 after TKA, resulting in an incremental cost-effectiveness ratio of $18,300 per QALY. For high-risk patients, TKA increased QALE from 5.713 to 6.594 QALY, yielding a cost-effectiveness ratio of $28,100 per QALY. At all risk levels, TKA was more costly and less effective in low-volume centers than in high-volume centers. Results were insensitive to variations of key input parameters within policy-relevant, clinically plausible ranges. The greatest variations were seen for the quality of life gain after TKA and the cost of TKA. CONCLUSIONS: Total knee arthroplasty appears to be cost-effective in the US Medicare-aged population, as currently practiced across all risk groups. Policy decisions should be made on the basis of available local options for TKA. However, when a high-volume hospital is available, TKAs performed in a high-volume hospital confer even greater value per dollar spent than TKAs performed in low-volume centers.
BACKGROUND:Total knee arthroplasty (TKA) relieves pain and improves quality of life for persons with advanced knee osteoarthritis. However, to our knowledge, the cost-effectiveness of TKA and the influences of hospital volume and patient risk on TKA cost-effectiveness have not been investigated in the United States. METHODS: We developed a Markov, state-transition, computer simulation model and populated it with Medicare claims data and cost and outcomes data from national and multinational sources. We projected lifetime costs and quality-adjusted life expectancy (QALE) for different risk populations and varied TKA intervention and hospital volume. Cost-effectiveness of TKA was estimated across all patient risk and hospital volume permutations. Finally, we conducted sensitivity analyses to determine various parameters' influences on cost-effectiveness. RESULTS: Overall, TKA increased QALE from 6.822 to 7.957 quality-adjusted life years (QALYs). Lifetime costs rose from $37,100 (no TKA) to $57 900 after TKA, resulting in an incremental cost-effectiveness ratio of $18,300 per QALY. For high-risk patients, TKA increased QALE from 5.713 to 6.594 QALY, yielding a cost-effectiveness ratio of $28,100 per QALY. At all risk levels, TKA was more costly and less effective in low-volume centers than in high-volume centers. Results were insensitive to variations of key input parameters within policy-relevant, clinically plausible ranges. The greatest variations were seen for the quality of life gain after TKA and the cost of TKA. CONCLUSIONS:Total knee arthroplasty appears to be cost-effective in the US Medicare-aged population, as currently practiced across all risk groups. Policy decisions should be made on the basis of available local options for TKA. However, when a high-volume hospital is available, TKAs performed in a high-volume hospital confer even greater value per dollar spent than TKAs performed in low-volume centers.
Authors: A D Paltiel; A L Fuhlbrigge; B T Kitch; B Liljas; S T Weiss; P J Neumann; K M Kuntz Journal: J Allergy Clin Immunol Date: 2001-07 Impact factor: 10.793
Authors: Paul R Fortin; John R Penrod; Ann E Clarke; Yvan St-Pierre; Lawrence Joseph; Patrick Bélisle; Matthew H Liang; Diane Ferland; Charlotte B Phillips; Nizar Mahomed; Michael Tanzer; Clement Sledge; Anne H Fossel; Jeffrey N Katz Journal: Arthritis Rheum Date: 2002-12
Authors: Sofia de Achaval; Liana Fraenkel; Robert J Volk; Vanessa Cox; Maria E Suarez-Almazor Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: J D Ament; T P Stryjewski; S Pujari; S Siddique; G N Papaliodis; J Chodosh; C H Dohlman Journal: Eye (Lond) Date: 2010-12-24 Impact factor: 3.775
Authors: E Losina; M E Daigle; L G Suter; D J Hunter; D H Solomon; R P Walensky; J M Jordan; S A Burbine; A D Paltiel; J N Katz Journal: Osteoarthritis Cartilage Date: 2013-02-04 Impact factor: 6.576
Authors: S C Kim; N Choudhry; J M Franklin; K Bykov; M Eikermann; J Lii; M A Fischer; B T Bateman Journal: Osteoarthritis Cartilage Date: 2017-04-19 Impact factor: 6.576
Authors: Derek S Stenquist; Scott A Elman; Aileen M Davis; Laura M Bogart; Sarah A Brownlee; Edward S Sanchez; Adianez Santiago; Roya Ghazinouri; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2015-01 Impact factor: 4.794